Biosense Webster Develops First AF Ablation Catheter Following Atrionix Buy
This article was originally published in The Gray Sheet
J&J/Cordis' $62.8 mil. cash acquisition of Atrionix rounds out Biosense Webster's electrophysiology product line with a catheter-based ablation approach to atrial fibrillation (AF).
You may also be interested in...
Implantable defibrillator therapy for the nearly 4 mil. atrial fibrillation patients not requiring ventricular defibrillation is at least three to five years away, Northwestern University electrophysiologist Alan Kadish, MD, indicated at the recent Lehman Brothers Healthcare Conference in Orlando, Florida.
Major Chinese biopharma contract services group WuXi Biologics' share price plummeted after it said external factors would contribute to it missing original revenue targets this year in multiple areas.